Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.63 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576959 | 1.00 | CYP11B1 (0.63) | CYP11B1CYP11B2CYP19A1KCNH2CYP3A4 | |
| SCHEMBL3567244 | 1.00 | CYP11B1 (0.63) | CYP11B1CYP11B2CYP19A1KCNH2CYP3A4 | |
| SCHEMBL3579561 | 0.87 | CYP11B2 (0.61) | CYP11B1CYP11B2CYP19A1KCNH2 | |
| SCHEMBL3563209 | 0.86 | CYP11B1 (0.45) | CYP11B1CYP11B2CYP19A1CYP3A4MAPK1 | |
| SCHEMBL3567442 | 0.86 | CYP11B1 (0.45) | CYP11B1CYP11B2CYP19A1CYP3A4MAPK1 | |
| SCHEMBL3578115 | 0.86 | CYP11B1 (0.45) | CYP11B1CYP11B2CYP19A1CYP3A4MAPK1 | |
| SCHEMBL3567431 | 0.86 | CYP11B1 (0.45) | CYP11B1CYP11B2CYP19A1CYP3A4MAPK1 | |
| SCHEMBL3570956 | 0.86 | CYP11B1 (0.45) | CYP11B1CYP11B2CYP19A1CYP3A4MAPK1 | |
| SCHEMBL3579225 | 0.86 | CYP11B1 (0.45) | CYP11B1CYP11B2CYP19A1CYP3A4MAPK1 | |
| SCHEMBL3575534 | 0.80 | CYP11B1 (0.39) | CYP11B1CYP11B2CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | claimed |
| EP-1537114-B8 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2007-10-03 | — | — | EP | claimed |
| EP-1537114-B1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2006-08-09 | — | — | EP | claimed |
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | claimed |
| EP-1537114-A1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | Novartis AG (CH) | 2005-06-08 | — | — | EP | claimed |
| WO-2004014914-A1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2004-02-19 | — | — | WO | claimed |
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| EP-1537114-B8 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| EP-1537114-B1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| EP-1537114-A1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | Novartis AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004014914-A1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | CYP11B1, CYP27A1, CYP17A1 | CYP11B1 1/4885CYP11B2 6/4885CYP19A1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.